Septerna (NASDAQ:SEPN) Trading Down 8% – Here’s What Happened

Septerna, Inc. (NASDAQ:SEPN) dropped 8% on Thursday . The company traded as low as $40.30 and last traded at $40.41. 175,984 shares were traded during trading, a decline of 51% from the average daily volume of 362,388 shares. The stock had previously closed at $43.93.

Analyst Ratings Changes

A number of research firms recently commented on SEPN. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. Truist Financial increased their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Stifel Nicolaus set a $49.00 price target on Septerna in a report on Tuesday, August 11th. HC Wainwright increased their target price on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $52.44.

Septerna Trading Down 1.9%

The firm has a market capitalization of $1.87 billion, a price-to-earnings ratio of -74.07 and a beta of 2.29. The firm’s 50-day moving average is $36.85 and its 200 day moving average is $30.28.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.14. The company had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. Analysts predict that Septerna, Inc. will post -1.36 EPS for the current year.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 15,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $35.51, for a total transaction of $532,650.00. Following the transaction, the senior vice president directly owned 96,412 shares in the company, valued at approximately $3,423,590.12. This trade represents a 13.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samira Shaikhly sold 11,798 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $30.06, for a total transaction of $354,647.88. Following the completion of the sale, the insider directly owned 793 shares of the company’s stock, valued at $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 72,828 shares of company stock worth $2,684,314. Corporate insiders own 5.80% of the company’s stock.

Institutional Trading of Septerna

A number of large investors have recently added to or reduced their stakes in SEPN. Group One Trading LLC grew its holdings in Septerna by 111.8% during the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock valued at $26,000 after purchasing an additional 8,955 shares during the period. Global Retirement Partners LLC purchased a new stake in Septerna in the 4th quarter worth approximately $35,000. Russell Investments Group Ltd. bought a new position in shares of Septerna in the third quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Septerna in the 4th quarter worth $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Septerna in the fourth quarter valued at $61,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.